Hikma Pharmaceuticals Plc Hikma & GP Pharm signs license & supply agreement
October 22 2012 - 5:13AM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
22 October 2012
Hikma signs license and supply agreement with GP Pharm for its
leading oncology compound
London, 22 October 2012 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (NASDAQ Dubai: HIK) today announces the signing of a
license and supply agreement for the registration and marketing of
Lutrate(R) 1 month, GP Pharm's leading anti-cancer compound, for
the Middle East and North Africa ("MENA") region. Lutrate(R) 1
month (leuprolide acetate 3.75 mg) is a hormonal androgen
deprivation therapy to prevent tumor growth in patients with
advanced prostate cancer.
Cancer is one of the leading causes of death in MENA. Prostate
cancer is the third most prevalent type of cancer in the region,
with an estimated 25,000 new cases diagnosed each year. With men
over 60 most often affected, the incidence of prostate cancer is
expected to increase dramatically as the population in MENA
ages.
Under the terms of the agreement, Hikma will have the licensing
rights to register, market and distribute Lutrate(R) 1 month in 23
countries across MENA. Hikma will also become the partner of choice
in the MENA region for GP Pharm's pipeline of oncology
products.
Mazen Darwazah, Hikma's Vice Chairman and CEO of MENA said,
"Hikma is committed to improving the treatment of cancer in the
region through the development of our oncology product portfolio.
We are pleased to be licensing this innovative injectable
treatment, which has excellent potential and complements our
portfolio and pipeline. It is in line with Hikma's aim to deliver a
reliable supply of high quality pharmaceutical products to MENA
that reduce patients' dependency on a single source for
treatment."
Dr. Berta Ponsati, GP Pharm's CEO said, "The success of
Lutrate(R) 1 month is a direct reflection of GP Pharm's dedication
and commitment to the development of new oncology treatments. We
are excited about the potential for this important product in the
MENA region and we look forward to working with Hikma."
--- ENDS ---
Enquiries
Hikma Pharmaceuticals PLC
Susan Ringdal, Investor Relations Director +44 (0)20 7399 2760/
07776 477 050
FTI Consulting +44 (0)20 7831 3113
Ben Atwell /Julia Phillips/Jonathan Birt/Matthew Cole
About Lutrate(R)
Lutrate(R) (leuprolide acetate 3.75 mg) belongs to a group of
drugs called agonists of luteinising hormone-releasing hormone
(LHRH), which are drugs that reduce testosterone (sex hormone).
Lutrate(R) 1 month has been approved in 23 countries in the
European Union, including Spain, Germany, the UK and Italy. It is
expected to be filed in the USA shortly and in a number of other
countries worldwide. Other presentations of Lutrate(R) are
currently under development by GP Pharm in 3 Month and 6 Month
depots.
About GP Pharm
GP Pharm, is a Spanish biopharmaceutical company located in
Barcelona. Its activities are focused on research, development,
production and marketing of injectable products within the urology
and oncology fields, some of them based on proprietary drug
delivery systems. These technological platforms include
microspheres and liposomes. The company works on the complete
development of these drugs, from the preclinical studies until the
launch to the market. These specialities are marketed either under
GP's brands or through licenses.
About Hikma
Hikma Pharmaceuticals is a fast growing multinational group
focused on developing, manufacturing and marketing a broad range of
both branded and non branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based principally in the
Middle East and North Africa (MENA) region, where it is a market
leader, the United States and Europe. In 2011, Hikma achieved
revenues of US$918.0 million and profit attributable to
shareholders of US$80.1 million.
About Hikma Oncology
Hikma is considered one of the pioneers in the oncology
therapeutic category in the MENA region, through both its in-house
R&D capabilities and through its strong and continuous
partnerships with multinational companies. Hikma's mission is to
provide the health sector with a wide variety of oncology products
covering innovative therapies, biosimilars and branded generics on
a global scale. Currently Hikma has two oncology manufacturing
facilities located in Germany and Jordan, with registrations in
many countries including the United States, Germany, Portugal and
in the MENA region.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEANEAAEPAFEF
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024